ReviewCurrent heart failure reports2017
Endothelial Glycocalyx as Biomarker for Cardiovascular Diseases: Mechanistic and Clinical Implications.
Review in Current heart failure reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it.
- C-Reactive Protein, Interleukin-6, Trimethylamine-N-Oxide, Syndecan-1, Nitric Oxide, and Tumor Necrosis Factor Receptor-1 in Heart Failure with Preserved Versus Reduced Ejection Fraction: a Meta-Analysis.Current heart failure reports · 2023Pooled it
- Endothelial damage in septic shock patients as evidenced by circulating syndecan-1, sphingosine-1-phosphate and soluble VE-cadherin: a substudy of ALBIOS.Critical care (London, England) · 2021Trial
- Relationship between serum circulating Syndecan-1 levels and myocardial fibrosis and major adverse cardiovascular events in elderly patients with atrial fibrillation.Heart and vessels · 2026Article
- Exploring Glycocalyx shedding markers: A comparative analysis of plasma markers among premenopausal and postmenopausal women.Physiological reports · 2026Article
- Beyond blood pressure: a comprehensive overview of clinical indices in shock and tissue hypoperfusion.Acute and critical care · 2026Article
- The Role of Endothelial Glycocalyx in the Pathophysiology of Chronic Kidney Disease and Hypertension: From Molecular Mechanisms to Clinical Biomarkers.Life (Basel, Switzerland) · 2026Review
- Prognostic value of circulating glypican-4 in chronic heart failure.Journal of molecular medicine (Berlin, Germany) · 2026Article
- Association between circulating biomarkers of endothelial glycocalyx degradation and postoperative acute kidney injury in patients undergoing cardiac surgery with cardiopulmonary bypass.Frontiers in surgery · 2026Article
- Fucoidan as a renal protectant: mechanistic insights and therapeutic implications of endothelial glycocalyx targeting.Frontiers in pharmacology · 2026Review
- Association between glucosamine use and albuminuria in the UK: a cohort and Mendelian randomisation study.BMJ open · 2025Article
- High Salt Intake and Atherosclerosis Progression-Not Only via Blood Pressure: A Narrative Review.Nutrients · 2025Review
- Assessment of Selected Endothelial Damage Biomarkers in the Determination of Endothelial Damage in Cats With Gingivostomatitis.Veterinary medicine and science · 2025Article
- Systemic Sclerosis: A Key Model of Endothelial Dysfunction.Biomedicines · 2025Review
- Cardiovascular Risk and Its Presentation in Chronic Kidney Disease.Journal of clinical medicine · 2025Review
- Glycocalyx Disintegration Is Associated with Mortality in Chronic Heart Failure.Journal of clinical medicine · 2025Article
- Comparative electron microscopic visualization of the lung alveolar epithelial glycocalyx with different staining and labeling methods.Journal of anatomy · 2025Article
- Evaluation of circulating glypican 4 as a novel biomarker in disease - A comprehensive review.Journal of molecular medicine (Berlin, Germany) · 2025Review
- Chronic Inflammatory Diseases and Cardiovascular Risk: Current Insights and Future Strategies for Optimal Management.International journal of molecular sciences · 2025Review
- Rivaroxaban as a Protector of Oxidative Stress-Induced Vascular Endothelial Glycocalyx Damage via the IQGAP1/PAR1-2/PI3K/Akt Pathway.Journal of vascular research · 2025Article
- The Endothelial Glycocalyx in Pig-to-Baboon Cardiac Xenotransplantation-First Insights.Biomedicines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionThe endothelial surface layer is covered with abundant proteoglycans, of which syndecans and glycosaminoglycans are major constituents. RECENT
findingsAmong the endothelial glycocalyx (eGC) constituents, syndecan-1 (sdc1) is a main component, and an elevated serum level of sdc1 may indicate the degradation of eGC. In patients with ischemic heart disease or heart failure, elevation of serum sdc1 has been associated with worsening cardiac and renal function; however, the causal relationship between degradation of eGC and clinical outcomes is unclear. Herein, we review the previous literature on eGC in cardiovascular and noncardiovascular diseases and their clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.